T-cell Acute Lymphoblastic Leukemia

Oncology·MeSH: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Prevalence

8.0 / 100K

Incidence

1.8 / 100K/yr

2 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Frequently asked questions

How many drugs are in development for T-cell Acute Lymphoblastic Leukemia?

BioSniper tracks 2 drugs in development for T-cell Acute Lymphoblastic Leukemia across 2 companies.

How many clinical trials target T-cell Acute Lymphoblastic Leukemia?

There are 2 clinical trials targeting T-cell Acute Lymphoblastic Leukemia tracked by BioSniper.

What is the prevalence of T-cell Acute Lymphoblastic Leukemia?

The estimated prevalence of T-cell Acute Lymphoblastic Leukemia is approximately 8.0 per 100,000 population.

Deep-dive into T-cell Acute Lymphoblastic Leukemia

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    T-cell Acute Lymphoblastic Leukemia — Drugs in Development & Clinical Trials | BioSniper